Skip to main content
SpringerLink
Log in

Combined Use of Pharmaceutical Agents

  • Chapter
  • First Online:
Medical Treatment of Glaucoma

  • 625 Accesses

Abstract

A combination of anti-glaucoma drugs is often required to achieve the target intraocular pressure when treating glaucoma. The efficacy and safety of combining these drugs are discussed in the first part of this chapter. Since patients with glaucoma also often suffer from systemic illnesses, such as hypertension, cardiovascular disease, and respiratory diseases, we also discuss the potential problems associated with glaucoma medications and systemic therapies for these conditions in this chapter. Elevated intraocular pressure or glaucoma can occur following many ophthalmic therapeutic procedures. How to identify and treat this type of glaucoma is discussed. Finally, combined uses of systemic and topical agents to control higher IOP are briefly discussed at the end of the chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucoma. Arch Ophthalmol. 2002;120(6):701–13.

    Article  Google Scholar 

  2. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943–53.

    Article  CAS  Google Scholar 

  3. Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma. 1999;8(1):24–30.

    Article  CAS  Google Scholar 

  4. Manni G, Centofanti M, Parravano M, et al. A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients. Graefes Arch Clin Exp Ophthalmol. 2004;242(9):767–70.

    Article  Google Scholar 

  5. Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs. monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120(7):915–22.

    Article  CAS  Google Scholar 

  6. Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma. 2001;10(3):220–6.

    Article  CAS  Google Scholar 

  7. Erdogan H, Toker I, Arici MK, et al. A short-term study of the additive effect of latanoprost 0.005% and brimonidine 0.2%. Jpn J Ophthalmol. 2003;47(5):473–8.

    Article  CAS  Google Scholar 

  8. Mundorf T, Noecker RJ, Earl M. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. Adv Ther. 2007;24:302–9.

    Article  CAS  Google Scholar 

  9. Arici MK, Topalkara A, Guler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol. 1998;22(1):37–42.

    Article  Google Scholar 

  10. Chiselita D, Apatachioae I, Poiata I. The ocular hypotensive effect of the combination of latanoprost with dorzolamide. Oftalmologia. 1999;46(4):39–45.

    CAS  PubMed  Google Scholar 

  11. Franks W, Brinzolamide Study Group. Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2006;22(9):1643–9.

    Article  CAS  Google Scholar 

  12. Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin. 2005;21(4):503–8.

    Article  CAS  Google Scholar 

  13. Nakamoto K, Yasuda N. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma. J Glaucoma. 2007;16(4):352–7.

    Article  Google Scholar 

  14. Langman MJ, Lancashire RJ, Cheng KK, et al. Systemic hypertension and glaucoma: mechanisms in common and co-occurrence. Br J Ophthalmol. 2005;89(8):960–3.

    Article  CAS  Google Scholar 

  15. Khawaja AP, Chan MP, Broadway DC, et al. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study. Ophthalmology. 2014;121(8):1501–7.

    Article  Google Scholar 

  16. Deokule S, Weinreb RN. Relationships among systemic blood pressure, intraocular pressure, and open-angle glaucoma. Can J Ophthalmol. 2008;43(3):302–7.

    Article  Google Scholar 

  17. Tielsch JM, Katz J, Sommer A, et al. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol. 1995;113(2):216–21.

    Article  CAS  Google Scholar 

  18. Hayreh SS, Zimmerman MB, Podhajsky P, et al. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994;117(5):603–24.

    Article  CAS  Google Scholar 

  19. Muskens RP, de Voogd S, Wolfs RC, et al. Systemic antihypertensive medication and incident open-angle glaucoma. Ophthalmology. 2007;114(12):2221–6.

    Article  Google Scholar 

  20. Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med. 2003;97(10):1094–101.

    Article  CAS  Google Scholar 

  21. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137(9):715–25.

    Article  CAS  Google Scholar 

  22. Kaiserman I, Kaiserman N, Elhayany A, et al. Topical beta-blockers are not associated with an increased risk of treatment for depression. Ophthalmology. 2006;113(7):1077–80.

    Article  Google Scholar 

  23. Honavar SG, Goyal M, Majji AB, et al. Glaucoma after pars plana vitrectomy and silicone oil injection for complicated retinal detachments. Ophthalmology. 1999;106(1):169–76. discussion 177.

    Article  CAS  Google Scholar 

  24. Hines MW, Jost BF, Fogelman KL. Oculab Tono-Pen, Goldmann applanation tonometry, and pneumatic tonometry for intraocular pressure assessment in gas-filled eyes. Am J Ophthalmol. 1988;106(2):174–9.

    Article  CAS  Google Scholar 

  25. Stjernschantz JW. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2001;42(6):1134–45.

    CAS  PubMed  Google Scholar 

  26. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol. 2000;11(2):94–100.

    Article  CAS  Google Scholar 

  27. Karesh JW, Nirankari VS. Factors associated with glaucoma after penetrating keratoplasty. Am J Ophthalmol. 1983;96(2):160–4.

    Article  CAS  Google Scholar 

  28. Foulks GN. Glaucoma associated with penetrating keratoplasty. Ophthalmology. 1987;94(7):871–4.

    Article  CAS  Google Scholar 

  29. Goldberg DB, Schanzlin DJ, Brown SI. Incidence of increased intraocular pressure after keratoplasty. Am J Ophthalmol. 1981;92(3):372–7.

    Article  CAS  Google Scholar 

  30. Zimmerman TJ, Krupin T, Grodzki W, et al. The effect of suture depth on outflow facility in penetrating keratoplasty. Arch Ophthalmol. 1978;96(3):505–6.

    Article  CAS  Google Scholar 

  31. Olson RJ, Kaufman HE. A mathematical description of causative factors and prevention of elevated intraocular pressure after keratoplasty. Invest Ophthalmol Vis Sci. 1977;16(12):1085–92.

    CAS  PubMed  Google Scholar 

  32. Polack FM. Graft rejection and glaucoma. Am J Ophthalmol. 1986;101(3):294–7.

    Article  CAS  Google Scholar 

  33. Olson RJ, Kaufman HE, Zimmerman TJ. Effects of timolol and Daranide on elevated intraocular pressure after aphakic keratoplasty. Ann Ophthalmol. 1979;11(12):1833–6.

    CAS  PubMed  Google Scholar 

  34. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, et al. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina. 2008;28(4):573–80.

    Article  Google Scholar 

  35. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–14.

    Article  Google Scholar 

  36. Inatani M, Iwao K, Kawaji T, et al. Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study. Am J Ophthalmol. 2008;145(4):676–81.

    Article  CAS  Google Scholar 

  37. Galor A, Margolis R, Brasil OM, et al. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology. 2007;114(10):1912–8.

    Article  Google Scholar 

  38. Francois J. The importance of the mucopolysaccharides in intraocular pressure regulation. Investig Ophthalmol. 1975;14(3):173–6.

    CAS  Google Scholar 

  39. Scherer WJ, Hauber FA. Effect of latanoprost on intraocular pressure in steroid-induced glaucoma. J Glaucoma. 2000;9(2):179–82.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology & Visual Science, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China

    Junyi Chen & Xinghuai Sun

  2. NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China

    Junyi Chen & Xinghuai Sun

  3. Shanghai Key Laboratory of Visual Impairment and Restoration (Fudan University), Shanghai, China

    Junyi Chen & Xinghuai Sun

  4. State Key Laboratory of Medical Neurobiology, Institutes of Brain Science and Collaborative Innovation Center for Brain Science, Fudan University, Shanghai, China

    Xinghuai Sun

Authors
  1. Junyi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinghuai Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xinghuai Sun .

Editor information

Editors and Affiliations

  1. Eye & ENT Hospital, Shanghai Medical College of Fudan University, Shanghai, China

    Xinghuai Sun

  2. Eye & ENT Hospital, Shanghai Medical College of Fudan University, Shanghai, China

    Yi Dai

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chen, J., Sun, X. (2019). Combined Use of Pharmaceutical Agents. In: Sun, X., Dai, Y. (eds) Medical Treatment of Glaucoma. Springer, Singapore. https://doi.org/10.1007/978-981-13-2733-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-2733-9_6

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-2732-2

  • Online ISBN: 978-981-13-2733-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation